Shaping Global Life Sciences Strategy by Mapping Value, HTA, and Payer Trends

The client established a new, above-brand, cross-functional steering committee that would shape the company’s global policy and advocacy strategy. The committee needed a mechanism to track and analyze extensive information on trends in value, HTA, and payer policies across major markets in priority therapeutic areas such as oncology, specialty drugs, and vaccines. The committee also sought information on opportunities to engage with key multilateral organizations and global value influencers. In addition to monitoring these developments, the client aimed to translate this information into comprehensive, multi-level strategies in prioritized therapeutic areas across markets.

We created a three-stage quarterly workflow to provide in-depth business intelligence on the client’s markets and therapeutic areas of interest.

First, we worked with the client to tier priority markets (i.e., China, France, Germany, Spain, Italy, Japan, Australia, Brazil, Canada, the United Kingdom, and the United States) and international organizations (e.g., the World Health Organization, the Professional Society for Health Economics and Outcomes Research [ISPOR]). Our team of analysts monitored policy developments across those markets and organizations, focusing on changes and emerging trends expected to impact the client’s portfolio.

Second, we worked with Avalere Health’s International Experts Group to identify in-country experts to discuss key policy issues flagged and analyze the likely impacts of emerging value, HTA, and payer policy trends for select therapeutic areas in each prioritized market. With these in-country experts, we developed recommendations for the global steering committee as it sought to craft its own policy positions and determine when and how to advocate for those positions in different markets.

Third, we presented to the global steering committee the results of our policy scanning and expert interviews, providing high-level trend analyses and offering recommendations on position development and strategic policy action across markets and therapeutic areas.

The client’s global steering committee has used our quarterly analyses and recommendations to develop in-depth business intelligence on emerging trends in value, HTA, and payer policies in priority international markets and therapeutic areas, helping the organization to establish a strong, above-brand policy and access strategy worldwide. These quarterly reports serve as pre-read decks for steering committee meetings and the recommendations contained in the reports guide steering committee agendas.